In experimental models polyribonucleotides, either alone or in combination with various polycations, are potent immunomodulators, inducers of interferons, and antitumor compounds. However, emerging clinical and preclinical results suggest they may have useful therapeutic roles of types not yet described with interferons. Thus, further Phase I and Phase II clinical trials are warranted to define their potential usefulness in humans.
Received June 11, 1985; accepted June 11, 1985.
Address correspondence and reprint requests to Dr. E. C. Borden at Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison, WI 53792, U.S.A.
© Lippincott-Raven Publishers.